Skip Navigation

Journal of Antimicrobial Chemotherapy 2009 63(Supplement 1):i41-i43; doi:10.1093/jac/dkp082
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sinkó, J.
Right arrow Articles by Anaissie, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinkó, J.
Right arrow Articles by Anaissie, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Articles

Summary and comments

Janos Sinkó1, Bart Jan Kullberg2, John E. Edwards3,4 and Elias Anaissie5,6,*

1 Department of Bone Marrow Transplantation, Szent László Hospital, Budapest, Hungary 2 University Medical Centre St Radboud, Nijmegan University Centre for Infections, Nijmegan, The Netherlands 3 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA 4 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, Torrance, CA, USA 5 Myeloma Institute for Research and Therapy, 4301 West Markham MS 776, Little Rock, AR 2205, USA 6 UAMS, Little Rock, AR 72205, USA

* Corresponding author. Tel: +1-501-686-8250; Fax: +1-501-686-6442; E-mail: anaissieeliasj@uams.edu

The first 150 words of the full text of this article appear below.


   Monotherapy
 
Empirical monotherapy of febrile neutropenic patients represents a lifetime's achievement for the few brave pioneers. Unravelling the inverse correlation between the number of circulating granulocytes and incidence of infection drew attention to a specific patient population, namely those with fever and neutropenia. At that time, the outlook for those with Gram-negative bacteraemia was dismal, so recognition of those at risk made immediate antimicrobial treatment possible before microbiological results became available. Initially, the goals of empirical therapy could only be achieved by using combinations of antimicrobials; typically one or more β-lactams plus an aminoglycoside. The development of safe β-lactam antibiotics with a broader spectrum of activity and more potent anti-Pseudomonas activity led some to consider the possibility of . . . [Full Text of this Article]


   Moulds
 

   Prophylaxis
 

   Empirical therapy
 

   Pre-emptive therapy
 

   Future developments
 

   Mucositis
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?